세계의 콕사키바이러스 감염 치료 시장 보고서(2025년)

Coxsackievirus Infections Treatment Global Market Report 2025

US $ 4,490 ￦ 6,342,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,167,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,992,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

콕사키바이러스 감염증 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 연간 평균 성장률(CAGR) 8.0%로 성장할 전망이며, 42억 3,000만 달러로 성장이 예측됩니다. 예측 기간 동안 성장의 원동력은 콕사키바이러스 감염 이환율 상승, 예방 헬스케어 중시 고조, 신흥 경제국에서 의료 접근성 확대, 지지 요법 제품 채용 확대, 항바이러스 요법에 대한 수요 고조, 치료 프로토콜 진보, 연구 개발 자금 확대, 바이러스성 질환에 대한 의식 고조, 신흥 경제국에서 의료 지출 증가입니다. 이 기간에 예상되는 주요 동향으로는 신속 진단 도구 개발, 치료 예측을 위한 인공지능 이용, 원격 치료를 위한 원격 의료 통합, 분자진단 진보, 표적을 좁힌 항바이러스제 개발, 웨어러블 건강 모니터링 장치 이용, 맞춤형 의료 확대, 디지털 헬스 솔루션 통합, 백신 전달 시스템 혁신 및 유효성을 높이기 위한 병용요법 개발 등이 있습니다.

수족구병(HFMD)으로 이어지는 바이러스 감염의 발생이 증가하고 있는 것이 콕사키바이러스 감염 치료 시장의 확대를 견인할 것으로 예측됩니다. HFMD는 발열, 구내염, 손발 발진이 특징으로 주로 콕사키바이러스 A16과 엔테로바이러스 71에 의해 발생하는 일반적으로 소아가 이환되는 바이러스성 질환입니다. 감염자와의 밀접한 접촉, 비위생, 호흡기 비말 및 오염된 표면으로의 노출 등의 요인이 감염 확산에 기여합니다. 콕사키바이러스 감염 치료는 통증완화, 수분공급, 해열 등의 지지요법을 제공함으로써 증상 관리에 중점을 두고 있습니다. 예를 들면, 2024년 4월, 인도네시아 보건부(MoH)는, 1분기에 6,500건의 HFMD 증례를 보고해, 2023년에 기록된 1만 1,000건의 절반 이상을 차지했습니다. 그 결과 HFMD의 유병률 증가가 콕사키바이러스 감염 치료 시장의 성장에 박차를 가하고 있습니다.

콕사키바이러스 감염 치료 분야의 주요 기업은 예방 효과를 높이고 감염률을 낮추고 공중 보건 결과를 개선하기 위해 다가 불활성화 백신을 개발하기 위해 노력하고 있습니다. 이들 백신에는 여러 병원체와 균주의 불활성화형이 포함되어 있어 여러 감염병에 대한 방어를 제공합니다. 예를 들면, 2022년 3월, 미국의 바이오 의약품 회사 Provention Bio Inc.는, 1형 당뇨병(T1D)의 자가 면역에 관련하는 CVB주를 표적으로 한 다가불활화 콕사키바이러스 B(CVB) 백신 후보인 PRV-101의 퍼스트인 인간 PROVENT 시험으로부터 얻은 양호한 최종 해석 결과를 발표했습니다. PRV-101은 비활성화된 CVB 혈청형을 면역계에 도입함으로써 감염을 야기하지 않으면서 신체가 여러 개의 주식을 인식하고 그에 대한 면역을 구축하는 것을 돕습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향 및 전략

제4장 시장-거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석 및 전략 분석 프레임워크

• 세계의 콕사키바이러스 감염 치료 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인 및 억제요인)
• 최종 이용 산업의 분석
• 세계의 콕사키바이러스 감염 치료 시장 : 성장률 분석
• 세계의 콕사키바이러스 감염 치료 시장 실적 : 규모 및 성장(2019-2024년)
• 세계의 콕사키바이러스 감염 치료 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
• 세계의 콕사키바이러스 감염 치료 전체 시장 규모(TAM)

제6장 시장 세분화

• 세계의 콕사키바이러스 감염 치료 시장 : 치료 유형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 항바이러스제
• 비스테로이드성 항염증제(NSAID)
• 코르티코스테로이드
• 지지요법
• 세계의 콕사키바이러스 감염 치료 시장 : 투여 경로별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 오랄
• 정맥내(IV)
• 주제
• 흡입
• 세계의 콕사키바이러스 감염 치료 시장 : 연령층별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 소아 환자
• 성인 환자
• 노인 환자
• 세계의 콕사키바이러스 감염 치료 시장 : 유통 채널별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 병원 약국
• 소매 약국
• 온라인 약국
• 세계의 콕사키바이러스 감염 치료 시장 : 최종 사용자별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 병원
• 외래 진료소
• 재택 케어 설정
• 교육기관(보육원, 학교)
• 세계의 콕사키바이러스 감염 치료 시장 : 항바이러스약 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 뉴클레오시드 유사체
• 프로테아제 억제제
• 폴리머라제 억제제
• 세계의 콕사키바이러스 감염 치료 시장 : 비스테로이드성 항염증제(NSAIDs) 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 이부프로펜
• 아스피린
• 나프록센
• 디클로페낙
• 세계의 콕사키바이러스 감염 치료 시장 : 코르티코스테로이드 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 프레드니손
• 하이드로코르티손
• 메틸프레드니솔론
• 덱사메타손
• 세계의 콕사키바이러스 감염 치료 시장 : 지지 요법 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 체액 보충 요법
• 통증 관리
• 발열 관리
• 휴식 및 영양

제7장 지역별 및 국가별 분석

• 세계의 콕사키바이러스 감염 치료 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 세계의 콕사키바이러스 감염 치료 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도 및 기업 프로파일

• 콕사키바이러스 감염 치료 시장 : 경쟁 구도
• 콕사키바이러스 감염 치료 시장 : 기업 프로파일
  • Pfizer Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
  • Johnson & Johnson 개요, 제품 및 서비스, 전략 및 재무 분석
  • F. Hoffmann-La Roche AG 개요, 제품 및 서비스, 전략 및 재무 분석
  • Merck & Co. Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
  • AbbVie Inc. 개요, 제품 및 서비스, 전략 및 재무 분석

제31장 기타 주요 기업 및 혁신 기업

• Bayer AG
• Sanofi SA
• Bristol-Myers Squibb
• Thermo Fisher Scientific Inc.
• AstraZeneca plc
• Abbott Laboratories
• Novartis AG
• GSK plc
• Teva Pharmaceutical Industries Ltd.
• CSL Behring
• Grifols SA
• Aurobindo Pharma USA Inc.
• Dr. Reddy's Laboratories
• Octapharma AG
• Rochem International Inc

제32장 세계 시장 경쟁 벤치마킹 및 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문 및 전략

• 콕사키바이러스 감염 치료 시장(2029년) : 새로운 기회를 제공하는 국가
• 콕사키바이러스 감염 치료 시장(2029년) : 새로운 기회를 제공하는 부문
• 콕사키바이러스 감염 치료 시장(2029년) : 성장 전략
  • 시장 동향에 기초한 전략
  • 경쟁 전략

제36장 부록

AJY

영문 목차

영문목차

Coxsackievirus infection treatment involves managing symptoms rather than providing a direct antiviral cure. Care primarily focuses on supportive measures such as rest, hydration, fever reducers, and pain relievers to ease discomfort. In severe cases, medical intervention may be necessary to address complications such as viral meningitis or myocarditis.

The primary treatment options in the coxsackievirus infection treatment market include antiviral medications, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and supportive care. Antiviral medications are designed to inhibit the replication and spread of the virus within the body. These treatments are administered through various routes, including oral, intravenous (IV), topical, and inhalation, catering to pediatric, adult, and geriatric patients. The market operates through multiple distribution channels, such as hospital pharmacies, retail pharmacies, and online pharmacies, serving a range of end-users, including hospitals, outpatient clinics, home care settings, and educational institutions.

The coxsackievirus infections treatment market research report is one of a series of new reports from The Business Research Company that provides coxsackievirus infections treatment market statistics, including coxsackievirus infections treatment industry global market size, regional shares, competitors with a coxsackievirus infections treatment market share, detailed coxsackievirus infections treatment market segments, market trends and opportunities, and any further data you may need to thrive in the coxsackievirus infections treatment industry. This coxsackievirus infections treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The coxsackievirus infections treatment market size has grown strongly in recent years. It will grow from $2.87 billion in 2024 to $3.11 billion in 2025 at a compound annual growth rate (CAGR) of 8.3%. The growth during the historic period can be attributed to a higher prevalence of hand, foot, and mouth disease, increased awareness of viral infections, advancements in healthcare infrastructure, greater demand for pediatric care, rising healthcare expenditures, frequent outbreaks in Asia-Pacific countries, expanded government healthcare initiatives, and improved access to over-the-counter treatments.

The coxsackievirus infections treatment market size is expected to see strong growth in the next few years. It will grow to $4.23 billion in 2029 at a compound annual growth rate (CAGR) of 8.0%. The projected growth in the forecast period is driven by the rising incidence of coxsackievirus infections, a growing emphasis on preventive healthcare, expanded healthcare access in developing regions, increased adoption of supportive care products, higher demand for antiviral therapies, advancements in treatment protocols, greater funding for research and development, increased awareness of viral diseases, and rising healthcare spending in emerging economies. Key trends expected during this period include the development of rapid diagnostic tools, the use of artificial intelligence for treatment prediction, the integration of telemedicine for remote care, advancements in molecular diagnostics, the creation of targeted antiviral drugs, the use of wearable health monitoring devices, the expansion of personalized medicine, the integration of digital health solutions, innovations in vaccine delivery systems, and the development of combination therapies for enhanced efficacy.

The increasing occurrence of viral infections leading to hand, foot, and mouth disease (HFMD) is expected to drive the expansion of the coxsackievirus infections treatment market. HFMD is a viral illness commonly affecting children, marked by fever, mouth sores, and a rash on the hands and feet, primarily caused by coxsackievirus A16 and enterovirus 71. Factors such as close contact with infected individuals, poor hygiene, and exposure to respiratory droplets or contaminated surfaces contribute to its spread. Coxsackievirus infection treatment focuses on symptom management by providing supportive care, including pain relief, hydration, and fever control. For example, in April 2024, the Indonesian Ministry of Health (MoH) reported 6,500 HFMD cases in the first quarter of the year, making up more than half of the 11,000 cases recorded in 2023. Consequently, the increasing prevalence of HFMD is fueling the growth of the coxsackievirus infections treatment market.

Leading companies in the coxsackievirus infections treatment sector are working on polyvalent inactivated vaccines to enhance protection, lower infection rates, and improve public health outcomes. These vaccines contain inactivated forms of multiple pathogens or strains, offering defense against several infections. For instance, in March 2022, Provention Bio Inc., a US-based biopharmaceutical company, shared positive final analysis results from its first-in-human PROVENT study of PRV-101, a polyvalent inactivated coxsackievirus B (CVB) vaccine candidate targeting CVB strains linked to type 1 diabetes (T1D) autoimmunity. PRV-101 introduces inactivated CVB serotypes to the immune system, helping the body recognize and build immunity against multiple strains without causing infection.

In April 2023, Sanofi S.A., a France-based pharmaceutical company, acquired Provention Bio Inc. for an undisclosed sum. This acquisition enables Sanofi to add an innovative, fully owned, first-in-class therapy for type 1 diabetes to its core portfolio in general medicines while advancing its strategic shift toward differentiated products. Provention Bio Inc. is a US-based biopharmaceutical company specializing in coxsackievirus infections treatment through the development of PRV-101, a polyvalent vaccine candidate.

Major players in the coxsackievirus infections treatment market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb, Thermo Fisher Scientific Inc., AstraZeneca plc, Abbott Laboratories, Novartis AG, GSK plc, Teva Pharmaceutical Industries Ltd., CSL Behring, Grifols S.A., Aurobindo Pharma USA Inc., Dr. Reddy's Laboratories, Octapharma AG, Rochem International Inc, AdvaCare Pharma, and LGM Pharma.

North America was the largest region in the coxsackievirus infections treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in coxsackievirus infections treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the coxsackievirus infections treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The coxsackievirus infections treatment market consists of revenues earned by entities by providing services such as symptomatic relief, antiviral research, hospitalization, pain management and supportive care for coxsackievirus infections. The market value includes the value of related goods sold by the service provider or included within the service offering. The coxsackievirus infections treatment market also includes sales of antiviral medications, over-the-counter pain relievers, hydration solutions, and other supportive care products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Coxsackievirus Infections Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on coxsackievirus infections treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for coxsackievirus infections treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The coxsackievirus infections treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Antiviral Medications; Non-Steroidal Anti-Inflammatory Drugs (NSAIDs); Corticosteroids; Supportive Care
• 2) By Route Of Administration: Oral; Intravenous (IV); Topical; Inhalation
• 3) By Age Group: Pediatric Patients; Adult Patients; Geriatric Patients
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 5) By End-User: Hospitals; Outpatient Clinics; Home Care Settings; Educational Institutions (Daycare, Schools)
• Subsegments:
• 1) By Antiviral Medications: Nucleoside Analogues; Protease Inhibitors; Polymerase Inhibitors
• 2) By Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen; Aspirin; Naproxen; Diclofenac
• 3) By Corticosteroids: Prednisone; Hydrocortisone; Methylprednisolone; Dexamethasone
• 4) By Supportive Care: Fluid Replacement Therapy; Pain Management; Fever Management; Rest and Nutrition
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche AG; Merck & Co. Inc.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Coxsackievirus Infections Treatment Market Characteristics

3. Coxsackievirus Infections Treatment Market Trends And Strategies

4. Coxsackievirus Infections Treatment Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Coxsackievirus Infections Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Coxsackievirus Infections Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Coxsackievirus Infections Treatment Market Growth Rate Analysis
• 5.4. Global Coxsackievirus Infections Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Coxsackievirus Infections Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Coxsackievirus Infections Treatment Total Addressable Market (TAM)

6. Coxsackievirus Infections Treatment Market Segmentation

• 6.1. Global Coxsackievirus Infections Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antiviral Medications
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• Corticosteroids
• Supportive Care
• 6.2. Global Coxsackievirus Infections Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intravenous (IV)
• Topical
• Inhalation
• 6.3. Global Coxsackievirus Infections Treatment Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pediatric Patients
• Adult Patients
• Geriatric Patients
• 6.4. Global Coxsackievirus Infections Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.5. Global Coxsackievirus Infections Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Outpatient Clinics
• Home Care Settings
• Educational Institutions (Daycare, Schools)
• 6.6. Global Coxsackievirus Infections Treatment Market, Sub-Segmentation Of Antiviral Medications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nucleoside Analogues
• Protease Inhibitors
• Polymerase Inhibitors
• 6.7. Global Coxsackievirus Infections Treatment Market, Sub-Segmentation Of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ibuprofen
• Aspirin
• Naproxen
• Diclofenac
• 6.8. Global Coxsackievirus Infections Treatment Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prednisone
• Hydrocortisone
• Methylprednisolone
• Dexamethasone
• 6.9. Global Coxsackievirus Infections Treatment Market, Sub-Segmentation Of Supportive Care, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fluid Replacement Therapy
• Pain Management
• Fever Management
• Rest and Nutrition

7. Coxsackievirus Infections Treatment Market Regional And Country Analysis

• 7.1. Global Coxsackievirus Infections Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Coxsackievirus Infections Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Coxsackievirus Infections Treatment Market

• 8.1. Asia-Pacific Coxsackievirus Infections Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Coxsackievirus Infections Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Coxsackievirus Infections Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Coxsackievirus Infections Treatment Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Coxsackievirus Infections Treatment Market

• 9.1. China Coxsackievirus Infections Treatment Market Overview
• 9.2. China Coxsackievirus Infections Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Coxsackievirus Infections Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Coxsackievirus Infections Treatment Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Coxsackievirus Infections Treatment Market

• 10.1. India Coxsackievirus Infections Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Coxsackievirus Infections Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Coxsackievirus Infections Treatment Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Coxsackievirus Infections Treatment Market

• 11.1. Japan Coxsackievirus Infections Treatment Market Overview
• 11.2. Japan Coxsackievirus Infections Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Coxsackievirus Infections Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Coxsackievirus Infections Treatment Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Coxsackievirus Infections Treatment Market

• 12.1. Australia Coxsackievirus Infections Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Coxsackievirus Infections Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Coxsackievirus Infections Treatment Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Coxsackievirus Infections Treatment Market

• 13.1. Indonesia Coxsackievirus Infections Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Coxsackievirus Infections Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Coxsackievirus Infections Treatment Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Coxsackievirus Infections Treatment Market

• 14.1. South Korea Coxsackievirus Infections Treatment Market Overview
• 14.2. South Korea Coxsackievirus Infections Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Coxsackievirus Infections Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Coxsackievirus Infections Treatment Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Coxsackievirus Infections Treatment Market

• 15.1. Western Europe Coxsackievirus Infections Treatment Market Overview
• 15.2. Western Europe Coxsackievirus Infections Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Coxsackievirus Infections Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Coxsackievirus Infections Treatment Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Coxsackievirus Infections Treatment Market

• 16.1. UK Coxsackievirus Infections Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Coxsackievirus Infections Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Coxsackievirus Infections Treatment Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Coxsackievirus Infections Treatment Market

• 17.1. Germany Coxsackievirus Infections Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Coxsackievirus Infections Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Coxsackievirus Infections Treatment Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Coxsackievirus Infections Treatment Market

• 18.1. France Coxsackievirus Infections Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Coxsackievirus Infections Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Coxsackievirus Infections Treatment Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Coxsackievirus Infections Treatment Market

• 19.1. Italy Coxsackievirus Infections Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Coxsackievirus Infections Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Coxsackievirus Infections Treatment Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Coxsackievirus Infections Treatment Market

• 20.1. Spain Coxsackievirus Infections Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Coxsackievirus Infections Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Coxsackievirus Infections Treatment Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Coxsackievirus Infections Treatment Market

• 21.1. Eastern Europe Coxsackievirus Infections Treatment Market Overview
• 21.2. Eastern Europe Coxsackievirus Infections Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Coxsackievirus Infections Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Coxsackievirus Infections Treatment Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Coxsackievirus Infections Treatment Market

• 22.1. Russia Coxsackievirus Infections Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Coxsackievirus Infections Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Coxsackievirus Infections Treatment Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Coxsackievirus Infections Treatment Market

• 23.1. North America Coxsackievirus Infections Treatment Market Overview
• 23.2. North America Coxsackievirus Infections Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Coxsackievirus Infections Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Coxsackievirus Infections Treatment Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Coxsackievirus Infections Treatment Market

• 24.1. USA Coxsackievirus Infections Treatment Market Overview
• 24.2. USA Coxsackievirus Infections Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Coxsackievirus Infections Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Coxsackievirus Infections Treatment Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Coxsackievirus Infections Treatment Market

• 25.1. Canada Coxsackievirus Infections Treatment Market Overview
• 25.2. Canada Coxsackievirus Infections Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Coxsackievirus Infections Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Coxsackievirus Infections Treatment Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Coxsackievirus Infections Treatment Market

• 26.1. South America Coxsackievirus Infections Treatment Market Overview
• 26.2. South America Coxsackievirus Infections Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Coxsackievirus Infections Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Coxsackievirus Infections Treatment Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Coxsackievirus Infections Treatment Market

• 27.1. Brazil Coxsackievirus Infections Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Coxsackievirus Infections Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Coxsackievirus Infections Treatment Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Coxsackievirus Infections Treatment Market

• 28.1. Middle East Coxsackievirus Infections Treatment Market Overview
• 28.2. Middle East Coxsackievirus Infections Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Coxsackievirus Infections Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Coxsackievirus Infections Treatment Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Coxsackievirus Infections Treatment Market

• 29.1. Africa Coxsackievirus Infections Treatment Market Overview
• 29.2. Africa Coxsackievirus Infections Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Coxsackievirus Infections Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Coxsackievirus Infections Treatment Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Coxsackievirus Infections Treatment Market Competitive Landscape And Company Profiles

• 30.1. Coxsackievirus Infections Treatment Market Competitive Landscape
• 30.2. Coxsackievirus Infections Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Coxsackievirus Infections Treatment Market Other Major And Innovative Companies

• 31.1. Bayer AG
• 31.2. Sanofi S.A.
• 31.3. Bristol-Myers Squibb
• 31.4. Thermo Fisher Scientific Inc.
• 31.5. AstraZeneca plc
• 31.6. Abbott Laboratories
• 31.7. Novartis AG
• 31.8. GSK plc
• 31.9. Teva Pharmaceutical Industries Ltd.
• 31.10. CSL Behring
• 31.11. Grifols S.A.
• 31.12. Aurobindo Pharma USA Inc.
• 31.13. Dr. Reddy's Laboratories
• 31.14. Octapharma AG
• 31.15. Rochem International Inc

32. Global Coxsackievirus Infections Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Coxsackievirus Infections Treatment Market

34. Recent Developments In The Coxsackievirus Infections Treatment Market

35. Coxsackievirus Infections Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Coxsackievirus Infections Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Coxsackievirus Infections Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Coxsackievirus Infections Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료